Notch2 signaling sensitizes endothelial cells to apoptosis by negatively regulating the key protective molecule survivin

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Quillard, Thibaut ^a,b,c,d   Devalliere, Julie ^a,b,c   Chatelais, Mathias ^a,b,c   Coulon, Flora ^a,b,c   Séveno, Céline ^a   Romagnoli, Mathilde ^a,e   Nion, Sophie Barillé ^a   Charreau, Béatrice ^a,b,c  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NOTCH2 RECEPTOR; PROTEIN BCL 2; SURVIVIN; TUMOR NECROSIS FACTOR; X LINKED INHIBITOR OF APOPTOSIS; APOPTOSIS INDUCING FACTOR; BIRC5 PROTEIN, HUMAN; DRUG DERIVATIVE; MICROTUBULE ASSOCIATED PROTEIN; NOTCH2 PROTEIN, HUMAN; PROLINE; PROLINEDITHIOCARBAMATE; THIOCARBAMIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; CYTOLOGY; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; VASCULAR ENDOTHELIUM;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; DOWN-REGULATION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; PROLINE; RECEPTOR, NOTCH2; SIGNAL TRANSDUCTION; THIOCARBAMATES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77949517864     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008244     Document Type: Article

References (44)

1. Artavanis-Tsakonas S, Rand MD, Lake RJ (1999) Notch signaling: cell fate control and signal integration in development. Science 284: 770-776.
2. Iso T, Kedes L, Hamamori Y (2003) HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 194: 237-255.
3. Uyttendaele H, Marazzi G, Wu G, Yan Q, Sassoon D, et al. (1996) Notch4/int- 3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. Development (Cambridge, England) 122: 2251-2259.
4. Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, et al. (2001) Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev 108: 161-164.
5. Iso T, Hamamori Y, Kedes L (2003) Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 23: 543-553.
6. Gridley T (2007) Vascular biology: vessel guidance. Nature 445: 722-723.
7. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, et al. (2000) Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 14: 1343-1352.
8. Uyttendaele H, Ho J, Rossant J, Kitajewski J (2001) Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A 98: 5643-5648.
9. MacKenzie F, Duriez P, Wong F, Noseda M, Karsan A (2004) Notch4 Inhibits Endothelial Apoptosis via RBP-J{kappa}-dependent and -independent Pathways. J Biol Chem 279: 11657-11663.
10. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, et al. (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24: 8813-8822.
11. Pober JS (2002) Endothelial activation: intracellular signaling pathways. Arthritis Res 4 Suppl 3: S109-116.
12. Bach FH, Hancock WW, Ferran C (1997) Protective genes expressed in endothelial cells: a regulatory response to injury. Immunol Today 18: 483-486.
13. Quillard T, Coupel S, Coulon F, Fitau J, Chatelais M, et al. (2008) Impaired Notch4 activity elicits endothelial cell activation and apoptosis: implication for transplant arteriosclerosis. Arterioscler Thromb Vasc Biol 28: 2258-2265.
14. Coupel S, Leboeuf F, Boulday G, Soulillou JP, Charreau B (2004) RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic allograft nephropathy. J Am Soc Nephrol 15: 2429-2439.
15. Shawber C, Nofziger D, Hsieh JJ, Lindsell C, Bogler O, et al. (1996) Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. Development 122: 3765-3773.
16. Witt CM, Hurez V, Swindle CS, Hamada Y, Klug CA (2003) Activated Notch2 potentiates CD8 lineage maturation and promotes the selective development of B1 B cells. Mol Cell Biol 23: 8637-8650.
17. Fitau J, Bouday G, Coulon F, Quillard T, Charreau B (2006) The adaptor molecule LNK negatively regulates TNFalpha -dependent VCAM-1 expression in endothelial cells through inhibition of the ERK1 and 2 pathways. J Biol Chem.
18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Cailhier JF, Laplante P, Hebert MJ (2006) Endothelial apoptosis and chronic transplant vasculopathy: recent results, novel mechanisms. Am J Transplant 6: 247-253.
20. Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8: 61-70.
21. O'Connor DS, Schechner JS, Adida C, Mesri M, Rothermel AL, et al. (2000) Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 156: 393-398.
22. Sade H, Krishna S, Sarin A (2004) The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem 279: 2937-2944.
23. Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, et al. (2006) Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. FASEB J 20: 1009-1011.
24. Takeshita K, Satoh M, Ii M, Silver M, Limbourg FP, et al. (2007) Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res 100: 70-78.
25. Leong KG, Hu X, Li L, Noseda M, Larrivee B, et al. (2002) Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol 22: 2830-2841.
26. MacKenzie F, Duriez P, Larrivee B, Chang L, Pollet I, et al. (2004) Notch4- induced inhibition of endothelial sprouting requires the ankyrin repeats and involves signaling through RBP-Jkappa. Blood 104: 1760-1768.
27. Parr C, Watkins G, Jiang WG (2004) The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med 14: 779-786.
28. O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, et al. (2007) Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. The American Journal of Pathology 171: 1023-1036.
29. Hubmann R, Schwarzmeier JD, Shehata M, Hilgarth M, Duechler M, et al. (2002) Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood 99: 3742-3747.
30. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, et al. (2004) Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 64: 7787-7793.
31. Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, et al. (2007) Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS ONE 2: e576.
32. Florena AM, Tripodo C, Guarnotta C, Ingrao S, Porcasi R, et al. (2007) Associations between Notch-2, Akt-1 and HER2/neu expression in invasive human breast cancer: a tissue microarray immunophenotypic analysis on 98 patients. Pathobiology 74: 317-322.
33. Radtke F, Raj K (2003) The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer 3: 756-767.
34. Saito T, Chiba S, Ichikawa M, Kunisato A, Asai T, et al. (2003) Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 18: 675-685.
35. O'Neill CF, Urs S, Cinelli C, Lincoln A, Nadeau RJ, et al. (2007) Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol 171: 1023-1036.
36. Ong CT, Cheng HT, Chang LW, Ohtsuka T, Kageyama R, et al. (2006) Target selectivity of vertebrate notch proteins. Collaboration between discrete domains and CSL-binding site architecture determines activation probability. J Biol Chem 281: 5106-5119.
37. Wu L, Maillard I, Nakamura M, Pear WS, Griffin JD (2007) The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Blood 110: 3618-3623.
38. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, et al. (2002) Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 8: 987-994.
39. Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22: 8581-8589.
40. Kirkiles-Smith NC, Mahboubi K, Plescia J, McNiff JM, Karras J, et al. (2004) IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression. J Immunol 172: 1391-1396.
41. Romagnoli M, Trichet V, David C, Clement M, Moreau P, et al. (2007) Significant impact of survivin on myeloma cell growth. Leukemia 21: 1070-1078.
42. Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Mol Cancer Ther 5: 478-482.
43. Zwerts F, Lupu F, De Vriese A, Pollefeyt S, Moons L, et al. (2007) Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood 109: 4742-4752.
44. Wang GJ, Sui XX, Simosa HF, Jain MK, Altieri DC, et al. (2005) Regulation of vein graft hyperplasia by survivin, an inhibitor of apoptosis protein. Arterioscler Thromb Vasc Biol 25: 2081-2087.